Skip to content

Investigator

Atul Varadhachary

FANNIN PARTNERS, LLC · funded by NEI, NCI

Companies
1

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$1.3M

Summed across those awards.

First award
Apr 1, 2022

Latest Sep 1, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R43

    Developing Scg3 Raptamers as a novel targeted therapy for wet AMD

    $300k

    Sep 1, 2025NEIFANNIN PARTNERS, LLCNIH RePORTER · 11182159 (opens the source filing in a new tab)

  2. R44

    Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia

    $1000k

    Apr 1, 2022NCIFANNIN PARTNERS, LLCNIH RePORTER · 10598447 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources